Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

Cancer Science

Volumn 103, Issue 11, 2012, Pages 1979-1984

  Chen, Yongshun ^a   Wu, Xiaoyuan ^a   Bu, Shanshan ^a   He, Chunyu ^a   Wang, Wen ^a   Liu, Jinsong ^a   Guo, Wei ^a   Tan, Bo ^a   Wang, Yanxia ^b   Wang, Jianhua ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Central Hospital of Jiaozuo Coal Group   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84868203400     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02393.x     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Zhao P, Dai M, Chen WQ, Li N. Cancer trends in China. Jpn J Clin Oncol 2010; 40: 281-5.
3. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 2007; 8: 545-53.
4. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospectice randomized trial (RTOG 85-01). JAMA 1999; 281: 1623-7.
5. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006: CD002092.
6. Gwynne S, Hurt C, Evans M et al. Definitive chemoradiation for oesophageal cancer-a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 2011; 23: 182-8.
7. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Groups 94-05) phase III trials of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
8. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 2006; 326: 1593-8.
9. Baumann M, Krause M, Dikomey E et al. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother Oncol 2007; 83: 238-48.
10. Dewdney A, Capdevila J, Glimelius B et al. EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer (Abstract). J Clin Oncol 2011; 29: 3513.
11. Blumenschein GR Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B nonsmall-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29: 2312-8.
12. Kies MS, Harris J, Rotman MZ et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int J Radiat Oncol Biol Phys 2009; 75: S15.
13. Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008; 13: 39-50.
14. Sobin LH, Gospodarowics MK, Wittekind C. TNM Classification of Malignant Tumors, 7th edn. Oxford: Wiley-Blackwell, 2009.
15. Abramovitz M, Ordanic-Kodani M, Wang Y et al. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 2008; 44: 417-23.
16. Nomoto K, Tsuta K, Takano T et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006; 126: 1-8.
17. Morgan C, Brewster AE, Maughan TS et al. Patterns of failure after definitive chemo-radiation for inoperable carcinoma of the oesophagus. Clin Oncol 2004; 16: S15.2.
18. Ng T, Dipetrillo T, Purviance J et al. Multi-modality treatment of esophageal cancer: a review of the current status and future directions. Curr Oncol Rep 2006; 8: 174-82.
19. Mendelsohn J, Baird A, Fan Z. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J, Howley PM, Israel MA et al., eds. The Molecular Basis of Cancer. Philadelphia, PA: W.B. Saunders Company, 2001: 137-44.
20. Imclone. ImClone Systems Incorporated. Cetuximab: Epidermal Growth Factor Receptor (EGFR) Antibody, Version 9.0. ImClone Investigator Brochure. New York: ImClone Systems, Inc., 2003.
21. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-15.
22. Kang X, Patel D, Shi J. Anti-EGFR monoclonal antibody cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface. Eur J Cancer 2002; 38: S149.
23. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005; 10: 590-601.
24. Gibson MK, Abraham SC, Wu TT et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-8.
25. Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004; 8: 448-53.
26. Sunpaweravong P, Sunpaweravong S, Puttawibul P et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 111-9.
27. Safran H, Suntharalingam M, Dipetrillo T et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008; 70: 391-5.
28. Lledo G, Michel P, Dahan L et al. Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX) (Abstract). J Clin Oncol 2011; 29 (Suppl 4); 8.
29. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
30. Janmaat ML. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-9.
31. Brenner B, Ilson DH, Minsky BD. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004; 22: 45-52.
32. Safran H, DiPetrillo T, Akerman P et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 405-9.
33. Gatzemeier U, von Pawel J, Vynnychenko I et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12: 30-7.
34. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.